Camlin Fine Sciences Valuation Multiples

Discover Camlin Fine Sciences' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Trayal Korporacija, Avantium, Synthomer, Flugger Group and more.

Camlin Fine Sciences Overview

About Camlin Fine Sciences

Camlin Fine Sciences Ltd is engaged in research, development, manufacturing, commercializing, and marketing of specialty chemicals and blends. These chemicals are used in food, feed, animal and pet nutrition and industrial products. The Company has only one reportable segment, namely, Speciality Chemicals. The company's product portfolio consists of Shelf life solutions, Aroma ingredients, Performance chemicals and Health & Wellness. Shelf life extension solutions include antioxidant solutions which are used to increase the shelf life of oils and. Aroma vertical includes a production of Vanillin and Ethyl Vanillin. Performance Chemicals consist of Guaiacol, Veratrole, TBC, and MEHQ and are used in sectors such as food flavoring, pharmaceuticals intermediate fragrance industry.


Founded

1993

HQ

India

Employees

661

Sectors

Financials (LTM)

Revenue: $199M
EBITDA: $18M

EV

$278M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Camlin Fine Sciences Financials

Camlin Fine Sciences reported last 12-month revenue of $199M and EBITDA of $18M.

In the same LTM period, Camlin Fine Sciences generated $96M in gross profit, $18M in EBITDA, and $10M in net income.


Camlin Fine Sciences P&L

In the most recent fiscal year, Camlin Fine Sciences reported revenue of $179M and EBITDA of $11M.

Camlin Fine Sciences is profitable as of last fiscal year, with gross margin of 39%, EBITDA margin of 6%, and net margin of 2%.

See analyst estimates for Camlin Fine Sciences
LTMLast FY202320242025202620272028
Revenue$199M$179M$169M$170M$177M
Gross Profit$96M$70M$74M$77M$73M
Gross Margin48%39%44%45%41%
EBITDA$18M$11M$8M$17M$14M
EBITDA Margin9%6%5%10%8%
EBIT Margin6%3%6%8%4%
Net Profit$10M$3M($6M)($13M)($1M)
Net Margin5%2%(4%)(8%)(1%)
Net Debt-$59M---

Financial data powered by Morningstar, Inc.

Camlin Fine Sciences Stock Performance

Camlin Fine Sciences has current market cap of $215M, and enterprise value of $278M.


Camlin Fine Sciences' stock price is $1.12.

Camlin Fine Sciences has an EPS (earnings per share) of $0.02.

See more trading valuation data for Camlin Fine Sciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$278M$215M-1.4%---$0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Camlin Fine Sciences Valuation Multiples

Camlin Fine Sciences trades at 1.4x EV/Revenue multiple, and 15.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Camlin Fine Sciences

Camlin Fine Sciences Financial Valuation Multiples

As of August 14, 2026, Camlin Fine Sciences has market cap of $215M and EV of $278M.

Camlin Fine Sciences has a P/E ratio of 21.7x.

LTMLast FY202320242025202620272028
EV/Revenue1.4x1.6x1.6x1.6x1.6x
EV/EBITDA15.5x24.7x32.9x16.4x20.3x
EV/EBIT21.8x56.2x28.4x19.7x35.7x
EV/Gross Profit2.9x4.0x3.8x3.6x3.8x
P/E21.7x74.0x(36.2x)(16.0x)(145.7x)
EV/FCF(83.4x)108.3x74.9xn/m183.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Camlin Fine Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Camlin Fine Sciences Margins & Growth Rates

Camlin Fine Sciences grew revenue by 29% and EBITDA by 162% in the last fiscal year.

In the most recent fiscal year, Camlin Fine Sciences reported gross margin of 39%, EBITDA margin of 6%, and net margin of 2%.

See estimated margins and future growth rates for Camlin Fine Sciences

Camlin Fine Sciences Margins

Last FY202420252026202720282029
Gross Margin39%45%41%48%
EBITDA Margin6%10%8%11%
EBIT Margin3%8%4%8%
Net Margin2%(8%)(1%)5%
FCF Margin1%0%1%(1%)

Camlin Fine Sciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth29%1%4%23%
Gross Profit Growth67%5%(6%)45%
EBITDA Growth162%101%(19%)82%
EBIT Growth339%44%(45%)124%
Net Profit Growth349%125%(89%)(811%)
FCF Growth(255%)(78%)85%(255%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Camlin Fine Sciences Operational KPIs

Camlin Fine Sciences' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Camlin Fine Sciences' Rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Camlin Fine Sciences' Rule of X is 68% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Camlin Fine Sciences
LTMLast FY202320242025202620272028
Rule of 4032%34%---
Bessemer Rule of X66%68%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue-2%1%1%1%
G&A Expenses to Revenue-3%3%2%3%
Opex to Revenue-36%38%37%37%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Camlin Fine Sciences Competitors

Camlin Fine Sciences competitors include Trayal Korporacija, Avantium, Synthomer, Flugger Group, Hudson Technologies, Grupa Azoty Puławy, XRF Scientific, Solar Foods, Gurit Holding and H&R Gruppe.

Most Camlin Fine Sciences public comparables operate across Chemicals.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Trayal Korporacija3.1x-124.4x-
Avantium19.0x8.7x(15.5x)(9.6x)
Synthomer0.5x0.5x16.4x5.7x
Flugger Group0.8x0.8x6.7x6.6x
Hudson Technologies0.9x0.8x8.9x9.6x
Grupa Azoty Puławy0.2x-35.7x-
XRF Scientific4.3x3.8x15.2x14.2x
Solar Foods1116.3x172.6x(147.0x)(65.1x)

This data is available for Pro users. Sign up to see all Camlin Fine Sciences competitors and their valuation data.

Start Free Trial

Camlin Fine Sciences VC Funding History

Before going public, Camlin Fine Sciences raised $23M in total equity funding, across 1 round.


Camlin Fine Sciences Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Nov-17Undisclosed stage-$23M-Camlin Fine Sciences Limited conducted a Qualified Institutional Placement (QIP) on November 23, 2017, raising total funds of 5,567.65 (likely in INR crore based on context) through allotment of equity shares, with ₹1 per share as nominal value and the balance as share premium. The annual report for FY 2017-18 confirms this event but provides no details on post-money valuation, pricing, or investor identities. Earlier in FY17, the company sought shareholder approval for potential fundraising up to ₹250 crore via QIP or other methods, including pricing compliant with SEBI ICDR floor price with possible 5% discount. The company operates as an integrated manufacturer focusing on shelf life solutions (antioxidants), aroma ingredients, health, and wellness products. Financial statements for periods around 2017, such as unaudited results to June 30, 2017, and FY17 annual report, are referenced but do not extract specific revenue or EBITDA figures in the provided excerpts. A subsidiary, CFS Antioxidantes de Mexico, reported consolidated statements for an irregular period starting May 4, 2016, following acquisition of 65% of Dresen Group, but no parent-level metrics are detailed. No traction metrics, competitive context, use of funds, or valuation multiples are mentioned in relation to the 2017 round. Promoters include individuals like Ashish Dandekar and Anagha Dandekar, along with entities such as Camart Finance Limited and Infinity Holdings, as noted in later documents.

Acquisitions by Camlin Fine Sciences

Camlin Fine Sciences has acquired 3 companies to date.

Last acquisition by Camlin Fine Sciences was on February 25th 2025. Camlin Fine Sciences acquired Vinpai for $15M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Camlin Fine Sciences

Vinpai
Ningbo Wanglong Flavors and Fragrances Co.
Dresen Quimica S.A de C.V.
Description
Vinpai SA is an ingredient tech that offers manufacturers natural alternatives to chemical additives. The Company is an ingredientist that designs, manufactures and markets complementary and ranges of functional ingredients based on algae, plants, minerals and fibers. These ingredients have the function of texturing, stabilizing, preserving, flavoring and/ or enriching the recipes of the food industry, cosmetics, well-being, and health. Vinpai offers manufacturers a complete offer including the supply of functional ingredients, sometimes combined in premix, as well as support for the formulation and the launch of industrial production with the management of the ramp-up with the transition from the lab to the factory.
Ningbo Wanglong Flavors and Fragrances Co. is a medium-sized Ningbo-based producer researching, developing, and manufacturing flavors and fragrances as food additives. The company handles import and export agency services for related goods and technologies in China.
Dresen Quimica S.A de C.V. is a Mexico-headquartered manufacturer of specialty chemical intermediates for animal feed, human food, and industrial applications. The company operates production facilities in Mexico, Guatemala, Peru, Colombia, and the Dominican Republic, supplying additives and preservatives to regional agribusinesses and manufacturers.
HQ CountryFranceChinaMexico
HQ City
-
Yuyao
Mexico City
Deal Date25 Feb 202525 Dec 20165 May 2016
Valuation$15M$12M$12M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Camlin Fine Sciences acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Camlin Fine Sciences

When was Camlin Fine Sciences founded?Camlin Fine Sciences was founded in 1993.
Where is Camlin Fine Sciences headquartered?Camlin Fine Sciences is headquartered in India.
How many employees does Camlin Fine Sciences have?As of today, Camlin Fine Sciences has over 661 employees.
Is Camlin Fine Sciences publicly listed?Yes, Camlin Fine Sciences is a public company listed on National Stock Exchange of India.
What is the stock symbol of Camlin Fine Sciences?Camlin Fine Sciences trades under CAMLINFINE ticker.
When did Camlin Fine Sciences go public?Camlin Fine Sciences went public in 2015.
Who are competitors of Camlin Fine Sciences?Camlin Fine Sciences main competitors include Trayal Korporacija, Avantium, Synthomer, Flugger Group, Hudson Technologies, Grupa Azoty Puławy, XRF Scientific, Solar Foods, Gurit Holding, H&R Gruppe.
What is the current market cap of Camlin Fine Sciences?Camlin Fine Sciences' current market cap is $215M.
What is the current revenue of Camlin Fine Sciences?Camlin Fine Sciences' last 12 months revenue is $199M.
What is the current revenue growth of Camlin Fine Sciences?Camlin Fine Sciences revenue growth (NTM/LTM) is 23%.
What is the current EV/Revenue multiple of Camlin Fine Sciences?Current revenue multiple of Camlin Fine Sciences is 1.4x.
What is the current EBITDA of Camlin Fine Sciences?Camlin Fine Sciences' last 12 months EBITDA is $18M.
What is Camlin Fine Sciences' EBITDA margin?Camlin Fine Sciences' last 12 months EBITDA margin is 9%.
What is the current EV/EBITDA multiple of Camlin Fine Sciences?Current EBITDA multiple of Camlin Fine Sciences is 15.5x.
What is the current FCF of Camlin Fine Sciences?Camlin Fine Sciences' last 12 months FCF is ($3M).
What is Camlin Fine Sciences' FCF margin?Camlin Fine Sciences' last 12 months FCF margin is (2%).
What is the current EV/FCF multiple of Camlin Fine Sciences?Current FCF multiple of Camlin Fine Sciences is (83.4x).
How many companies Camlin Fine Sciences has acquired to date?As of August 2026, Camlin Fine Sciences has acquired 3 companies.
What was the largest acquisition by Camlin Fine Sciences?$15M acquisition of Vinpai on 25th February 2025 was the largest M&A Camlin Fine Sciences has done to date.
What companies Camlin Fine Sciences acquired?Camlin Fine Sciences acquired Vinpai, Ningbo Wanglong Flavors and Fragrances Co., and Dresen Quimica S.A de C.V..
In how many companies Camlin Fine Sciences has invested to date?Camlin Fine Sciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Camlin Fine Sciences

Lists including Camlin Fine Sciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial